Screener
Denali Therapeutics Inc. DNLI Free cash flow
Free cash flow at other companies
Other financials
Where this comes from
Calculated from Denali Therapeutics Inc.’s reported figures.
The source filing: Denali Therapeutics Inc.’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:08 PM EDT
- Fiscal quarter
- Q4 FY2026
- Calendar quarter
- Q4 2026
- Accession
- 0001714899-26-000097
FAQ
- What is Denali Therapeutics Inc.'s free cash flow?
- Denali Therapeutics Inc. (DNLI) reported free cash flow of -$97.81M in Q2 2026.
- How has Denali Therapeutics Inc.'s free cash flow changed year-over-year?
- Denali Therapeutics Inc.'s free cash flow decreased by 22.9% year-over-year, from -$79.58M to -$97.81M.
- What is the long-term trend for Denali Therapeutics Inc.'s free cash flow?
- Over 4 years (2021 to 2025), Denali Therapeutics Inc.'s free cash flow has grown at a 17.7% compound annual growth rate (CAGR), from -$219.89M to -$422.1M.
- What does free cash flow mean?
- Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.
Ask your AI about Denali Therapeutics Inc.'s free cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude